| Can-Fite BioPharma (NYSE American: CANF) Appoints Univo Pharmaceuticals’ CEO to Board |
| |
|
Can-Fite BioPharma (NYSE American: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specifically to the A3 adenosine receptor (A3AR), addressing cancer, liver and inflammatory diseases, announced that Golan Bitton, CEO of Univo Pharmaceuticals (TASE:UNVO), was elected as a board member to Can-Fite.
Why It Matters: In September 2019, Can-Fite BioPharma and Univo Pharmaceutical, a medical cannabis company, entered into a collaboration agreement to co-develop cannabis derived pharmaceutical products based on the platform technology of Can-Fite in the fields of cancer, inflammatory, autoimmune, and metabolic diseases. Bitton has many years of managerial experience in the Israeli Ministry of Defense. During his tenure there, he Implemented and managed multi-million-dollar projects for the Israeli Government. Golan holds a B.A. in Economics and Business Management from Max Stern Academic College and Computer Engineering from Negev University. Golan is the founder of Univo Pharmaceuticals and is considered today as one of the leading worldwide experts in the cannabis arena.
Key Quote: “We welcome Golan as a board member and trust that his skills will be highly valuable to Can-Fite and also strengthen the collaboration in the cannabis arena, which is intended to lead to new intellectual property and novel pharmaceutical products." – Dr. Pnina Fishman, CEO
The Backstory: Can-Fite is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion-dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and the Company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date.
Disclosure
Can-Fite Biopharma (CANF) is a client of RedChip Companies, Inc. CANF agreed to pay RedChip Companies, Inc. a cash fee of $5,000 monthly, beginning in August 2019, and 16,500 shares of CANF Rule 144 stock for 6 months of RedChip investor awareness services and consulting services.
|
|
| |
|
| Cyclo Therapeutics (OTCQB: CTDH) Signs Master Service Agreement with Worldwide Clinical Trials |
| |
|
CTDH currently supports a Phase I clinical trial for NPC in the U.S., which recently completed enrollment (ClinicalTrials.gov NCT02939547); an Extension Protocol for the US study, which includes home-based infusions (NCT03893071); and a Phase I/II trial in Europe and Israel for NPC which is nearing completion of enrollment (NCT02912793). The Company will share its design of a pivotal trial in scientific advice meetings with regulators in the US and Europe in first and second quarters of 2020, respectively.
Key Quote: “We are very excited to take this next step in working with Worldwide, an industry leader in the rare disease and neurological disease space. Worldwide will play a vital role as we build and execute our clinical programs in NPC and Alzheimer’s Disease.” – N. Scott Fine, Chairman & CEO
The Backstory: CTDH currently supports a Phase I clinical trial for NPC in the U.S., which recently completed enrollment (ClinicalTrials.gov NCT02939547); an Extension Protocol for the US study, which includes home-based infusions (NCT03893071); and a Phase I/II trial in Europe and Israel for NPC which is nearing completion of enrollment (NCT02912793). The Company will share its design of a pivotal trial in scientific advice meetings with regulators in the US and Europe in first and second quarters of 2020, respectively.
Disclosure
Cyclo Therapeutics (CTDH) is a client of RedChip Companies, Inc. CTDH paid RedChip Companies, Inc. a fee of $30,000 per month for four months, beginning in August 2019, and a monthly fee of $7,500, beginning December 2019, for RedChip investor awareness services and consulting services. RedChip's CEO owns 146,128 shares of CTDH stock.
|
|
| |
|
| Digital Ally (NASDAQ: DGLY) Receives New Patent for Law Enforcement Technology |
| |
|
Digital Ally (NASDAQ: DGLY), which develops, manufactures and markets advanced video recording products for law enforcement, emergency management, fleet safety and security, announced the pending addition of U.S. Patent No. 10,521,675 (the “675 Patent”) to the Company’s patent portfolio.
Why It Matters: The ‘675 Patent is the first of its kind for the Company, allowing the software from the recording video cameras to scan film frame by frame to capture and store legible vehicle markings, such as license plate characters. The ‘675 Patent will be useful for law enforcement officers when conducting traffic stops and especially at nightfall when objects may be obscured by challenging lighting conditions and interfere with the camera’s ability to capture legible markings or characters. When a recording is activated by various triggers (i.e., vehicle sirens or signal lights) the recording camera system will initiate two base scans, considering ambient light levels, light gains, shutter speed and white balance. If vehicle markings are legibly captured, the system will automatically store and upload the frame in the Company’s back-office solution for the law enforcement agency’s use.
Key Quote: “The issuance of Patent ‘675 is very exciting for us. This is our first patent that utilizes computer recognition software. Our entire team at Digital Ally has worked hard and the ‘675 Patent marks the conclusion of a very successful year of innovation. We are excited for our prospects for the immediate and long-term future.” – Stan Ross, CEO
The Backstory: Headquartered in Lenexa, Kansas, DGLY specializes in the design and manufacturing of the highest quality video recording equipment and video analytic software. Digital Ally pushes the boundaries of technology in industries such as law enforcement, emergency management, fleet safety and security. Digital Ally’s complete product solutions include in-car and body cameras, cloud and local management software, and automatic recording technology. Digital Ally products are sold by domestic direct sales representatives and international distributors worldwide.
Disclosure
Digital Ally, Inc. (DGLY) is a client of RedChip Companies, Inc. DGLY agreed to pay RedChip Companies, Inc., a $7,500 monthly cash fee, beginning in September 2017, for RedChip investor awareness services.
|
|
| |
|
| Santa Fe Gold (OTC: SFEG) to Begin Recommissioning its Billali Mine |
| |
|
Santa Fe Gold (OTC: SFEG), a U.S. based mining company that currently ranks 9th out of the top ten US based mid-tier and junior precious metals companies (as cited by mining industry trade journal, The Northern Miner) with 148 mining claims covering 42 mine sites and potential mines, plans to begin recommissioning its Billali mine to substantially increase output of its economic grade, high silica vein gold and silver siliceous vein material
Key Quote: “We are very pleased to announce expected further increases in output and shipments from the already producing Jim Crow mine, soon be augmented by new production from what we believe will be higher potential output from the Billali Mine that is expected to continue well into the future in annual output. This should enable Santa Fe to ramp up production substantially over coming quarters and beyond. Thereafter, it is expected Santa Fe will begin preparations to commence production from its Gold King and Imperial Mines, as sustainable output is achieved from Billali and Jim Crow to maintainable levels. We believe production from multiple mines will have significant longer term impact on our bottom line.” – Brian Adair, Chairman
The Backstory: Santa Fe Gold is a US-based mining and exploration enterprise with 148 mining claims comprising 42 potential mines of which Jim Crow Gold and Silver Mine is already in production. Jim Crow is the first of 11 potential mines in the mining rich Steeple Rock Billali district, with additional mines expected to be brought into production soon. Santa Fe’s goal is to produce near term cash flows from its numerous mine sites, while creating a portfolio of high-quality exploration and bankable development projects, to ensure future revenue growth.
Disclosure
Santa Fe Gold Corp. (SFEG) is a client of RedChip Companies, Inc. SFEG agreed to pay RedChip Companies, Inc. 1,000,000 shares of Rule 144 stock for 12 months of RedChip investor awareness services and consulting services.
|
|
| |
|
| |
| Quote of the Week |
| |
"Higher returns, of course, come with more risk...the trade off is, yes, you get long-term outperformance ... but the volatility of returns is greater... That's the price you pay if you want exposure to a better-performing asset class."
- Samuel Dedio, Manager of the Artio U.S. Microcap Fund (JMCAX) |
|
|
|
|
|
|
|
